Increase in FeNO Levels Following IL5/IL5R-Targeting Therapies in Severe Asthma: A Case Series-Reference-Cited by-同舟云学术

Increase in FeNO Levels Following IL5/IL5R-Targeting Therapies in Severe Asthma: A Case Series

Published:2022-05 Issue: Volume:Volume 15 Page:691-701
ISSN:1178-6965
Container-title:Journal of Asthma and Allergy
language:en
Short-container-title:JAA

Author:

Pelletier Geneviève,Godbout Krystelle,Boulay Marie-Ève,Boulet Louis-Philippe,Morissette Mathieu C,Côté Andréanne

Publisher

Informa UK Limited

Subject

Pulmonary and Respiratory Medicine,Immunology and Allergy

Reference36 articles.

1. Recognition and management of severe asthma: A Canadian Thoracic Society position statement

2. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort

3. Global initiative for asthma. Difficult-to-treat & Severe asthma in adolescent and adult patients - diagnosis and management. Available from: www.ginasthma.org. Accessed May 5, 2022.

4. Importance of concomitant local and systemic eosinophilia in uncontrolled asthma

5. Diagnosis and Management of T2-High Asthma

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Remission Criteria and Serum Levels of Type 2 Inflammation Mediators during 24 Weeks of Treatment with the Anti-IL-5 Drug Mepolizumab in Patients with T2-High Severe Asthma;Diagnostics;2024-06-25

2. Long-Term Real-World Outcomes of Mepolizumab and Benralizumab Among Biologic-Naive Patients With Severe Eosinophilic Asthma: Experience of 3 Years’ Therapy;The Journal of Allergy and Clinical Immunology: In Practice;2023-09

3. Exploring the Interaction between Fractional Exhaled Nitric Oxide and Biologic Treatment in Severe Asthma: A Systematic Review;Antioxidants;2023-02-07

4. Benralizumab/mepolizumab;Reactions Weekly;2022-12-17

5. Use of FeNO to predict anti-IL-5 and IL-5R biologics efficacy in a real-world cohort of adults with severe eosinophilic asthma;Journal of Asthma;2022-11-15